Healthcare entity
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Brian Wolpin, the most common co-covered peer. We currently track 1 Healthcare story that mention daraxonrasib, all published on August 27, 2026.
Last mentioned: Aug 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Brian Wolpin, the most common co-covered peer. We currently track 1 Healthcare story that mention daraxonrasib, all published on August 27, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering daraxonrasib. Shared-story counts are live from our verified record — not editorial picks.
FDA Approval
FDA approves daraxonrasib (Rasonque) for metastatic pancreatic cancer, six months ahead of the regulatory deadline.
Breakthrough Therapy Designation
FDA grants daraxonrasib Breakthrough Therapy designation for advanced pancreatic cancer.
For healthcare providers and health systems, FDA approval of Rasonque introduces the first RAS-targeted oral therapy for metastatic pancreatic cancer, nearly doubling median overall survival from 6.6 to 13.2 months, with implications for treatment protocols, oncologist education, and patient access.
daraxonrasib is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
